Litcius/Paper detail

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo, Kenshi Suzuki, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Shinsuke Iida, Joan Bladé, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Anupa Kudva, Ming Qi, Jesús F. San Miguel

2021Clinical Lymphoma Myeloma & Leukemia56 citationsDOIOpen Access PDF

Topics & Concepts

MelphalanMedicineBortezomibHazard ratioPrednisoneInternal medicineDaratumumabMultiple myelomaGastroenterologyOncologySurgeryConfidence intervalMultiple Myeloma Research and TreatmentsAcute Myeloid Leukemia ResearchMultiple and Secondary Primary Cancers